ACM
BMRN icon

Accipiter Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Accipiter Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$3.4M Sell
47,120
-12,880
-21% -$846K 6.1% 10
2014
Q2 		$3.73M Buy
+60,000
New +$3.62M 6.9% 7

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Accipiter Capital Management's BMRN Position: Q3 2014 in Review

Accipiter Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 21% in Q3 2014, selling an estimated $846K and leaving 47,120 shares worth $3.4M. The position accounts for 6.1% of the portfolio, ranked #10.

Accipiter Capital Management first reported a position in BMRN in Q2 2014 and has held it in 2 quarters since. The position peaked at $3.73M in Q2 2014. 317 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

  • Accipiter Capital Management held 47,120 shares of BioMarin Pharmaceuticals worth $3.4M as of Q3 2014.
  • Accipiter Capital Management sold 12,880 BioMarin Pharmaceuticals shares in Q3 2014, an estimated $846K.
  • BioMarin Pharmaceuticals made up 6.1% of Accipiter Capital Management's portfolio in Q3 2014, its #10 holding.
  • Accipiter Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • Accipiter Capital Management's BioMarin Pharmaceuticals position peaked at $3.73M in Q2 2014.
  • 317 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on Accipiter Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.